As the world’s life sciences sector rebounds, Canadian drug developers are poised to prosper. But can the sector avoid getting hollowed out by acquisitive pharma giants?

Arch Biopartners is developing novel therapies designed to protect kidney function in both acute kidney injury (AKI) and

YouTube video by WebsEdgeMedicine

Obtain full 2026 CSN AGM info, agendas, and more.

Nile red spectroscopy to evaluate disease-specific lipid alterations in glomerular kidney disease, Swamy, Asha, Teo, Wulin, Bau, Jason T, Kline, Adrienne, Imanzadeh, Aysa, Chapman, Kevin, Andonegui, Graciela, Benediktsson, Hallgrimur, Muruve, Daniel A, Stys, Peter K, Chun, Justin

No drug-related adverse events have been assessed to date in Arch Biopartners’ Phase II trial of LSALT peptide for cardiac surgery–associated acute kidney injury (CS-AKI), and a blinded data review co...

Arch Biopartners Inc (ARCH:TSXV; ACHFF:OTCQB) is a therapeutic biotech company focused on developing novel, on-target drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The companys...

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD),

Background Prediction of cardiac surgery-associated acute kidney injury (CS-AKI) in pediatric patients is crucial to improve outcomes and guide clinical decision-making. This study aimed to develop a ...

This Framework will be Canada’s first comprehensive, evidence-based roadmap designed to transform kidney health outcomes across the country - and one that governments can use to inform policy, plannin...

New data reveals chronic kidney disease is claiming the lives of more Canadians than ever before. Kathy Le on the health crisis.

Acute kidney injury (AKI) is a common and serious complication of cardiac surgery, often linked to the use and duration of cardiopulmonary bypass (CPB). The Hemolysis Index (HI) has been proposed as a...

This article is published as part of a supplement supported by Kidney Disease: Improving Global Outcomes (KDIGO). The development and publication of this guideline were supported by KDIGO. The opinion...

Chronic kidney disease is a progressive condition that affects >10% of the general population worldwide, amounting to >800 million individuals. Chronic kidney disease is more prevalent in older indivi...

CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate ...

Sepsis-induced acute kidney injury (S-AKI) is one of the most serious life-threatening complications of sepsis. The pathogenesis of S-AKI is complex a…

ABSTRACTBackground and Hypothesis. We assessed disease progression among patients with immunoglobulin A nephropathy (IgAN) and characterized factors associ

Acute kidney injury (AKI) is a common medical condition that we encounter in our daily clinical practice. However, in certain cases, ascertaining the underlying cause of the AKI could be challenging a...

Despite significant advancements in oncology, conventional chemotherapy remains the primary treatment for diverse malignancies. Acute kidney injury (AKI) sta...

Scientific Reports - Attenuation of natural killer cell cytotoxicity by interaction between NKp30 of NK cells and dipeptidase 1 of colon cancer cells

Novo Nordisk stock fell after it said it would buy Akero Therapeutics for $54 a share in cash, and an additional $6 if it gets U.S. approval of Efruxifermin, it’s treatment for fatty liver disease.

Novo Nordisk is licensing exclusive global rights to the company's experimental treatment for rare blood and kidney diseases.

Cisplatin is a highly effective chemotherapeutic agent that has been used for more than 50 years for a variety of cancers; however, its use is limited by toxicity, including nephrotoxicity. In this in...

IntroductionChronic kidney disease (CKD) is a serious complication of diabetes, and the global burden of the disease is gradually increasing.MethodsThis stud...

As cases of chronic kidney disease emerge in outdoor laborers around the world, scientists are finding that repeated damage from prolonged extreme heat seems to be a leading factor to kidney failure

While CKD is common among US adults, people who have CKD can take steps to protect their kidneys.

Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of a $95 million series B, the company

IntroductionTo retrospectively investigate the clinical characteristics and risk factors of cardiac surgery associated-acute kidney injury (CS-AKI) progresse...

Addressing the burden of non-communicable diseases is a global public health priority. In this joint Consensus Statement, the American Society of Nephrology, the European Renal Association and the International Society of Nephrology highlight the need to recognize kidney disease as a key driver of premature mortality, in addition to other non-communicable diseases already prioritized by the World Health Organization.

Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that is light on capital yet still heavy on scientific innovation. | Sanofi is ...

Scientific Reports - Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023

Nine out of 10 people with chronic kidney disease only find out when it progresses to later stages. Here’s what we know about its risk factors—and why there's new reason to hope for more effective tre...

ObjectiveHospitalized patients, particularly those in the ICU, face a significant risk of acute kidney injury (AKI). Clinical practice guidelines (CPGs) that...